GSK plc
GSK
$38.58
$0.1750.46%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -29.53% | -46.81% | -57.52% | -72.22% | -67.46% |
| Total Depreciation and Amortization | 32.62% | 15.38% | 95.62% | 33.86% | -4.89% |
| Total Amortization of Deferred Charges | 7.16% | 7.16% | 5.24% | 5.24% | 5.24% |
| Total Other Non-Cash Items | 344.37% | 203.35% | -122.26% | 100.00% | 103.62% |
| Change in Net Operating Assets | -174.30% | 137.46% | 169.89% | 126.85% | 120.78% |
| Cash from Operations | -10.29% | -0.79% | 39.38% | 70.93% | 62.75% |
| Capital Expenditure | -4.15% | -9.37% | -9.67% | -12.47% | -17.50% |
| Sale of Property, Plant, and Equipment | 200.96% | 138.58% | -92.44% | -85.05% | -84.02% |
| Cash Acquisitions | 58.53% | 43.12% | 50.10% | 80.83% | 26.13% |
| Divestitures | -131.34% | -137.24% | -159.93% | -165.56% | 208.37% |
| Other Investing Activities | -101.46% | -15.45% | 853.91% | 805.89% | 264.94% |
| Cash from Investing | -69.43% | 19.54% | 105.55% | 106.90% | 74.61% |
| Total Debt Issued | 1,138.91% | 501.35% | -149.18% | -147.15% | -112.66% |
| Total Debt Repaid | 13.76% | 2.04% | 2.67% | 37.67% | 55.94% |
| Issuance of Common Stock | -36.36% | 66.67% | 90.91% | 5.26% | -4.35% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -11.71% | -11.75% | -6.56% | 0.10% | 23.73% |
| Other Financing Activities | -11.83% | -8.72% | 18.46% | -311.76% | -226.95% |
| Cash from Financing | 54.87% | 14.29% | -126.95% | -188.37% | 12.65% |
| Foreign Exchange rate Adjustments | 45.44% | 43.11% | -366.91% | -69.62% | -181.81% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,343.70% | 202.46% | 104.40% | 96.15% | 98.26% |